Latest news with #ACTIVATE
Techday NZ
30-07-2025
- Business
- Techday NZ
Vultr joins ACTIVATE AI ecosystem to boost global GPU access
Vultr has joined the ACTIVATE AI Ecosystem Partner Program developed by Parallel Works, providing flexible and vendor-neutral access to GPU resources for AI workloads across hybrid and multi-cloud environments. The announcement is part of the launch of Parallel Works' ACTIVATE AI Partner Ecosystem, which aims to simplify access to next-generation AI infrastructure and facilitate the deployment of AI at scale. Through the integration of Vultr's high-performance GPUs into the ACTIVATE AI control plane, users can access GPU resources on demand, avoiding vendor lock-in and reducing operational overhead traditionally associated with managing multi-cloud AI infrastructure. Meeting growing demand for AI resources As AI applications become more widespread, research teams and enterprises are consistently seeking ways to obtain the flexible computing needed to support training and deployment of large-scale models. Matthew Shaxted, CEO at Parallel Works, highlighted the increasing demand for integrated compute resources: "The global surge in AI adoption – from large language models to domain-specific applications – is driving demand for more than just GPU access. Organisations need flexible, integrated ecosystems to build, train and deploy AI at scale. Traditional infrastructure is too rigid, and managing fragmented tools across clouds slows innovation. Our Partner Ecosystem, combined with ACTIVATE AI, provides unified access to specialized compute – enabling an open, scalable AI ecosystem that puts control back in the hands of the user." The ACTIVATE AI Partner Ecosystem enables orchestration of AI workloads through a unified control plane that connects to a range of neocloud GPU providers. This connectivity supports container-based workflows, continuous integration and deployment pipelines, and distributed object storage. The service allows dynamic allocation and intelligent workload placement, supporting the collaborative needs of organisations with varying requirements. Industry partners and technical integration Alongside Vultr, the ecosystem brings onboard other GPU-as-a-service and aggregator partners such as Voltage Park, Canopy Wave, VALDI (a division of Storj), GPU Trader, and Shadeform. These collaborations expand GPU capacity and enable hybrid cloud bursting with distributed, vendor-neutral storage solutions. Kevin Cochrane, Chief Marketing Officer at Vultr, commented on the collaboration, stating, "Our partnership with Parallel Works reflects a joint commitment to driving AI innovation through an open ecosystem - making it easier, faster, and more cost-effective for customers to deploy AI at scale worldwide." Brandon Peccoralo, Vice President of Sales & Partnerships at Voltage Park, noted, "We are thrilled to be a part of the ACTIVATE AI Ecosystem Partner Program as it truly is connecting users to high-performance GPUs, giving teams access to the right compute for the right task. Together with the Parallel Works software platform and the Voltage Park scalable GPU cloud, customers can have the control and monitoring they want and moreover need when provisioning very expensive cloud resources. This will result in streamlined provisioning and a lower overall OPEX when leveraged properly." Hai Vo-Dinh, Senior Director of Product at Canopy Wave, added, "We are built to overcome the challenges of deploying AI at scale. Our partnership with Parallel Works does that and more – seamlessly and on-demand." Aggregators and infrastructure specialists Jacob Willoughby, Chief Technology Officer at VALDI, a division of Storj, said, "Valdi simplifies access to high-performance compute across clouds and platforms. With Parallel Works, users can orchestrate AI workloads faster and with less friction. Together, we're enabling a more open, scalable AI infrastructure." Ben Moore, Co-Founder and CEO at GPU Trader, stated, "We are dedicated to helping businesses unlock the power of HPC to drive their next breakthrough. Teaming with the ACTIVATE AI Ecosystem Partner Program helps organizations take advantage of the best of streamlined GPU and technology deployment." Ed Goode, Co-Founder and CEO at Shadeform, commented, "Shadeform was founded on the belief that developers should be able to freely choose where they run their compute workloads. We are pleased to be part of Parallel Works ACTIVATE AI ecosystem, working together to enable seamless, vendor-neutral access to the world's GPU supply chain." Technology and storage partners Jason Tuschen, CEO at QLAD, said, "Researchers and engineers running sensitive workloads need end-to-end trust in their Kubernetes environments. ACTIVATE is making that possible, and QLAD is proud to contribute workload-level protections that extend that trust to every mission-critical workflow." Dean Beeler, Co-Founder and CTO at Juice, remarked, "Juice's solution provides fine-grained control over GPU resources, enabling dynamic allocation, improved job scheduling, and higher overall utilization. In combination with ACTIVATE AI, HPC teams can increase session density per GPU and accelerate compute-intensive workflows, leading to faster innovation and stronger ROI on existing infrastructure." Jacob Willoughby, CTO at Storj, noted, "Storj provides high-performance, globally distributed storage that's both resilient and cost-efficient. Through ACTIVATE AI, teams gain seamless, vendor-neutral access to data across environments. Its storage built for modern AI - fast, scalable, and ready for what's next." Channel and reseller involvement Jim Kovach, Director of Business Development for HPC/AI at Pier Group, said, "It's an honor to be part of Parallel Works ACTIVATE AI Partner Program. Driving innovative AI technologies such as ACTIVATE AI into the education and research market helps our clients meet and exceed their technology goals." Michael Fedele, President and CEO at The Pinnacle Group, stated, "We take pride in providing our customers with technologies such as Parallel Works ACTIVATE AI that can not only seamlessly integrate with their environment but can efficiently scale as well." Shozo Takahashi, President and CEO at Core Micro Systems, Japan, commented, "Our partnership with Parallel Works marks a pivotal step towards expanding access to powerful AI and HPC platforms in Japan. By combining Parallel Works ACTIVATE with our AI/HPC Appliance based advanced micro and modular data center technologies, we are enabling organizations to harness the full potential of hybrid, edge, and multi-cloud computing with simplicity and speed." The ACTIVATE AI Ecosystem also includes global providers such as AWS, Google Cloud, Azure, and storage companies like Hammerspace, broadening the available infrastructure options for users needing a flexible, scalable, and vendor-neutral approach to AI and HPC deployments.
Business Wire
14-07-2025
- Business
- Business Wire
Parallel Works Named Finalist for 2025 CRN Tech Innovator Awards
CHICAGO--(BUSINESS WIRE)-- Parallel Works, provider of the ACTIVATE control plane for hybrid multi-cloud computing resources, today announced that CRN ®, a brand of The Channel Company, has selected Parallel Works as a 2025 CRN Tech Innovators Awards finalist for its ACTIVATE control plane in the Cloud Tools /Management category. 'Being named a CRN Tech Innovator finalist affirms our belief that the future of enterprise computing lies in unified, scalable platforms that empower partners and customers to achieve more with less complexity," said Matthew Shaxted, CEO, Parallel Works Share As HPC and artificial intelligence (AI) continue to converge, Parallel Works ACTIVATE delivers scalable AI solutions that optimize resource usage by leveraging partial compute, helping prevent the overprovisioning of costly resources, while empowering enterprises with the control and performance they need to scale smart, not just large. The annual CRN Tech Innovator Awards spotlights cutting-edge technology vendors in the IT channel. Parallel Works ACTIVATE simplifies how organizations access and manage cloud and hybrid compute environments, making it easier for channel partners to deliver scalable, secure, and value-added solutions. With built-in support for multi-cloud orchestration, policy management, and real-time budget controls, it accelerates cloud adoption, reduces operational complexity, and improves ROI—while offering tailored services that drive retention. With seamless provisioning, management, and shared compute resources at scale ACTIVATE can be used across on-premises, cloud, and hybrid environments. Acting as a central nervous system for distributed AI, it unifies AI and HPC workloads across diverse infrastructures, enabling the recapture of idle capacity with up to 20 percent more utilization while delivering immediate ROI. 'Each of the 2025 CRN Tech Innovators Awards finalists is a standout offering that reimagines what's possible in the IT channel,' said Jennifer Follett, VP, U.S. Content, and Executive Editor, CRN, The Channel Company. 'Each creates the opportunity to build bold solutions that solve real-world challenges for end users and drive success for channel partners. We congratulate our finalists for their commitment to innovation, partner success, and customer impact, and we can't wait to see how they continue to push technology boundaries forward.' ACTIVATE empowers businesses to innovate with a computing control plane that is scalable, flexible and vendor-neutral while enhancing technological advancements and optimizing workflows. It facilitates collaboration and enhances productivity through intuitive interfaces and API-driven processes, enabling flexible HPC cluster creation in the cloud. 'We built ACTIVATE to make powerful computing accessible, manageable, and collaborative across any environment,' said Matthew Shaxted, CEO of Parallel Works. 'Being named a CRN Tech Innovator finalist affirms our belief that the future of enterprise computing lies in unified, scalable platforms that empower partners and customers to achieve more with less complexity and greater efficiency.' CRN Tech Innovator finalists were selected in 33 distinct technology categories across areas such as cloud, storage, networking, and security by a panel of CRN editors after closely reviewing hundreds of vendor entries and solution provider testimonials. Finalists are selected based on multiple criteria, including key capabilities, uniqueness, technological ingenuity, and ability to address customer and partner technology needs. About Parallel Works Parallel Works ACTIVATE is a leading hybrid multi-cloud computing control plane, empowering teams with seamless provisioning, management, and sharing of compute resources at scale across on-premises and cloud environments with advanced cost control and budgeting features. ACTIVATE facilitates collaborative research and enhances productivity through intuitive interfaces and API-driven processes, enabling the operating system for complex enterprise computing environments. Visit Parallel Works at
Yahoo
20-05-2025
- Business
- Yahoo
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapy In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p<0.05) Final analysis mirrors the excellent safety profile of PS101 seen in the interim read-out and suggests a dose-response relationship The data supports the company's plans for its Phase 2 trial (ENACT) in patients with locally advanced or borderline resectable pancreatic cancer OSLO, Norway, May 20, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce the final and positive data set from its Phase 1 ACTIVATE trial. The trial investigated the use of EXACT's proprietary Acoustic Cluster Therapy with chemotherapy in hard-to-treat patients with liver metastases of colorectal origin. These encouraging clinical data provide proof of principle for the clinical application of ACT technology and offer strong support for initiating the ENACT Phase 2 study in pancreatic cancer, a disease with a high unmet medical need. "I am excited about the data from the ACTIVATE trial, which yet again underscore the attractive therapeutic proposition from our proprietary ACT technology. The strength of the response to treatment, the safety profile and its non-invasive nature points to a unique and highly differentiated therapeutic regimen. We continue our efforts to bring ACT to cancer patients as fast as possible. Building on the momentum of the ACTIVATE study, we are excited to be approaching the first patient dosing in our Phase 2 ENACT trial in locally advanced pancreatic cancer." said Per Walday, CEO of EXACT Therapeutics. The final results affirm the previously reported positive ACTIVATE outcomes and indicate the significant added efficacy of ACT with chemotherapy compared with chemotherapy alone. Among patients who responded to chemotherapy, tumor shrinkage was significantly greater with ACT and chemotherapy compared to chemotherapy alone in the same individuals (−29% vs. −7%, p<0.05). ACT treatment with EXACT's proprietary agent PS101 had a clear dose-response relationship. Shrinkage of tumour lesions was significantly greater in patients who received 40 µl/kg PS101 compared with 20 µl/kg PS101. In the group of patients who showed a response to chemotherapy in the control lesions, 3 out of 4 patients who received 40 µl/kg PS101 showed tumour shrinkage of more than 30% in diameter. Tumour shrinkage was seen in 6 out of 9 patients who received ACT with chemotherapy. PS101 was safe and well tolerated when given with chemotherapy. Chief Medical Officer of EXACT Therapeutics, Amir Snapir continued, "Today's update marks the successful completion of the ACTIVATE trial. The results give us great confidence in the treatment potential of the ACT technology for patients with solid tumours." EXACT Therapeutics is committed to advancing cancer therapies and sharing its research findings with the broader scientific community. The company plans to present the detailed data from the Phase 1 ACTIVATE trial in a future scientific publication and at a forthcoming medical conference. The company wishes to thank the patients, their families and the investigators for their participation and contribution to the ACTIVATE trial. About the Phase 1 ACTIVATE trial ACTIVATE is a multi-center, single arm, open-label Phase 1 trial to assess the safety and tolerability, pharmacokinetics, and preliminary anti-cancer activity of ACT treatment with the chemotherapy regimens FOLFOX or FOLFIRI in patients with liver metastases of colorectal origin. The trial is designed in the way that each patient serves as their own control, with primary assessment of anti-tumour activity consisting of within-patient comparison of radiographic responses between ACT-treated lesions (insonated plus chemotherapy) and control lesions (chemotherapy alone, non-insonated). Assessment was done at week 8 by blinded central review. The trial enrolled 11 hard-to-treat patients, hereof 9 evaluable, at sites in the United Kingdom. Additional information about the ACTIVATE trial is available at (NCT04021277). About Acoustic Cluster TherapyAcoustic Cluster Therapy (ACT®) consists of PS101 administered intravenously and insonated over a target tissue with ultrasound. PS101 is a formulation of microclusters of perfluorobutane microbubbles and perfluoromethylcyclopentane microdroplets. High frequency insonation causes PS101 to form larger ACT bubbles that are temporarily lodged in capillaries, followed by low frequency insonation, which induces oscillation of the lodged ACT bubbles, enhancing the delivery of the concurrently given chemotherapy to the target tissues. About EXACT TherapeuticsEXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: For further information, please contact: Per WaldayCEO EXACT TherapeuticsEmail: Forward looking statements:This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Parallel Works Appoints Decorated U.S. Army Veteran and Venture Capitalist Matthew Archuleta as Vice President of Operations
Archuleta to drive operational excellence and accelerate growth CHICAGO, April 24, 2025--(BUSINESS WIRE)--Parallel Works, provider of the ACTIVATE control plane for AI and HPC resources, today announced Matthew Archuleta as Vice President of Operations. A decorated U.S. Army Green Beret and investor, Archuleta brings mission-driven leadership, deep strategic insight and a proven track record of scaling operations. Archuleta joins Parallel Works from Connecticut Innovations, where he served as a senior investment associate, managing venture capital investments across AI, cybersecurity, fintech, and defense tech. He held board observer seats at several early and growth-stage startups. "Matthew's unique blend of combat-tested leadership, business acumen, and innovation-focused investing makes him the ideal choice to lead our operations through our next phase of growth," said Matthew Shaxted, founder and CEO of Parallel Works. "His precision, adaptability, and expertise in scalable systems will be invaluable to our customers and teams." Prior to his work in venture capital, Archuleta served as a U.S. Army Special Forces officer and Infantry officer, commanding elite teams in West Africa and the Middle East. He was awarded the Bronze Star for his leadership in Afghanistan and has been featured in The New York Times and Poets & Quants for his contributions to both national defense and business. Archuleta holds an MBA from the Yale School of Management, an MPA from Harvard Kennedy School, and a B.S. from the U.S. Military Academy at West Point. He has also served as an innovation officer for the Connecticut Army National Guard. "I'm excited to join the Parallel Works team," said Archuleta. "Every enterprise needs high-performance computing to compete in the age of AI. Parallel Works has the experience and vision to transition companies into the future right now. I look forward to leading the operations, building scalable systems and empowering our teams to deliver transformative results across engineering, science, and national security." About Parallel Works Parallel Works ACTIVATE is a computing control plane, empowering teams with seamless provisioning, management, and sharing of compute resources at scale across on-premises, cloud, and hybrid environments with advanced cost control and budgeting features. ACTIVATE facilitates collaborative research and enhances productivity through intuitive interfaces and API-driven processes, enabling flexible HPC cluster creation in the cloud. Visit Parallel Works at View source version on Contacts Press Contact Details:IGNITE Consulting, on behalf of Parallel WorksKim Pegnato | 781-835-7118 | parallelworks@ Sign in to access your portfolio
